Paul Hahn, MD, PhD, FASRS

upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD

Novel Investigational Approaches for the Treatment of Neovascular AMD

1:00 Retina specialists’ wish list for innovative therapies

8:43 Extending treatment intervals beyond four months

15:00 Need for long-term retinal fluid suppression

22:00 Helping patients facing end-stage vision loss

Videos

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

Novel Investigational Approaches For the Treatment of Neovascular AMD

To watch the video series component of this episode, click here.

Podcasts

1:05 Overview of faricimab and high-dose aflibercept

3:48 clinical trials for faricimab and high-dose aflibercept

9:12 Comparing the matched dose phase results in clinical trials

12:30 Potential impacts of Ang-2 inhibition

14:40 Real-world experience with faricimab

24:00 Choosing between faricimab vs high-dose aflibercept

29:00 Perspectives on retreatment criteria in clinical trials

33:00 Label differences between faricimab and high-dose aflibercept

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

Paul Hahn, MD, PhD, FASRS

Articles